Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications | Palmetto Peptides

PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Peptides for laboratory use only. Last Up

By Recovery & Performance Peptides Editorial Team

PT-141 vs Melanotan II: Comparative Analysis for Research Peptide Applications

Research Notice: This article covers research on Melanotan II (MT-2) research peptide and PT-141 research peptide — available from Palmetto Peptides for laboratory use only.

Last Updated: January 15, 2025

Research Use Only Disclaimer: Both PT-141 (Bremelanotide) and Melanotan II (MT-II) are sold exclusively for in vitro laboratory and preclinical research purposes. Neither compound is intended for human or veterinary use, consumption, or self-administration. All comparative information below is drawn from the peer-reviewed preclinical literature and is provided for scientific reference only.

When researchers are designing experiments that probe the melanocortin system, the choice between PT-141 and Melanotan II is not arbitrary. These compounds share a structural scaffold but differ in ways that directly affect which receptor subtypes they engage, how potently they activate signaling cascades in vitro, and what kinds of experimental questions they are best suited to answer. This article provides a detailed side-by-side comparison.

Last Updated: April 6, 2026 | Reading Time: Approximately 8 minutes | Author: Palmetto Peptides Research Team

Quick Answer

When researchers are designing experiments that probe the melanocortin system, the choice between PT-141 and Melanotan II is not arbitrary. These compounds share a structural scaffold but differ in ways that directly affect which receptor subtypes they engage, how potently they activate signaling cascades in vitro, and what kinds of experimental questions they are best suited to answer.

Structural Similarities and Differences

Both PT-141 and Melanotan II belong to the cyclic heptapeptide class of melanocortin analogs. They were developed from the same foundational research program at the University of Arizona, and both are derived structurally from alpha-melanocyte-stimulating hormone (alpha-MSH) with modifications designed to enhance stability and receptor affinity.

Melanotan II Structure

MT-II: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂

PT-141 Structure

PT-141: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

The difference at first glance appears minor: the C-terminal amide (NH₂) in MT-II versus the free carboxyl (-OH) in PT-141. However, this modification is pharmacologically meaningful, as the C-terminal chemistry affects the overall charge distribution of the peptide and influences its interaction with the extracellular domains of melanocortin receptor subtypes.

Both compounds retain the core features introduced in early SAR work: - Norleucine (Nle) substitution for improved oxidative stability - D-Phenylalanine for enhanced receptor affinity and protease resistance - Cyclic lactam bridge between Asp and Lys side chains for conformational rigidity

Structural Comparison at a Glance

C-terminal group

Amide (-NH₂)

Free carboxyl (-OH)

Cyclic lactam bridge

Yes

Norleucine at position 4

D-Phe at position 7

Molecular weight

~1024 Da

~1025 Da

CAS Number

121062-08-6

189691-06-3

Primary receptor targets

MC1R, MC3R, MC4R

MC3R, MC4R (MC1R lower)

Relative receptor selectivity

Broad (pan-agonist across MCRs)

More selective at MC3R/MC4R

Receptor Pharmacology: Where the Research Diverges

The most important practical difference between MT-II and PT-141 for laboratory researchers is their receptor selectivity profile.

Melanotan II: Broad Melanocortin Receptor Agonism

MT-II is frequently described in the literature as a nonselective or pan-agonist at melanocortin receptors. Its binding affinity is high across MC1R, MC3R, and MC4R subtypes, and it also shows activity at MC5R in some assay systems. This broad receptor engagement has made MT-II an extremely useful pharmacological tool for experiments that seek to activate or block the melanocortin system globally, as a general probe for melanocortin biology.

The MC1R activity of MT-II is particularly notable. MC1R is the primary pigmentation receptor, expressed on melanocytes. In animal models, MT-II produces visible pigmentation effects through this pathway. This provides a visible biological readout in certain in vivo model systems, which is useful as a pharmacodynamic marker in whole-animal preclinical studies.

However, for researchers who want to study MC3R or MC4R pathways specifically without simultaneously engaging MC1R and the associated pigmentation biology, MT-II's broad agonism is a limitation. It becomes difficult to attribute observed biological effects to a specific receptor subtype when multiple subtypes are activated simultaneously.

PT-141: Relative Selectivity for MC3R and MC4R

PT-141's receptor selectivity profile differs from MT-II in ways that are useful for receptor-specific research designs. In published radioligand binding assays, PT-141 shows comparatively reduced activity at MC1R relative to MT-II, while maintaining high affinity at MC3R and MC4R.

This means that PT-141 is a more selective tool for probing the MC3R and MC4R receptor subtypes in vitro without the full confound of concurrent MC1R activation. For researchers studying autonomic or central nervous system-relevant signaling pathways through MC4R (the most CNS-expressed melanocortin receptor subtype), PT-141 provides a more pharmacologically precise experimental lever than MT-II.

Potency Comparison in Cell-Based Assays

Quantitative comparison of MT-II and PT-141 potency is receptor subtype and assay system dependent, but generalizations from the published preclinical literature include:

At MC1R: MT-II is substantially more potent than PT-141 in cAMP accumulation assays at this subtype. This is consistent with MT-II's known pan-agonist profile.

At MC4R: Both compounds show high affinity in radioligand binding at MC4R, with EC50 values in published in vitro cAMP assays in the low to sub-nanomolar range. Direct potency comparisons vary by assay system and cell line.

At MC3R: Both show activity, with published Ki values in the nanomolar range. Relative potency at MC3R may differ between assay systems.

Pharmacokinetic Properties in Preclinical Models

In preclinical animal studies, MT-II and PT-141 both show improved metabolic stability compared to native alpha-MSH, a direct result of their shared cyclic structure, Nle substitution, and D-Phe incorporation. Both are resistant to standard proteolytic degradation.

Differences in C-terminal chemistry (amide vs. carboxyl) may affect plasma half-life in rodent models, but this distinction is primarily relevant to in vivo research designs. For in vitro experiments, both compounds are stable in cell culture conditions for the duration of standard incubation periods.

Choosing Between PT-141 and MT-II: A Research Decision Framework

Broad MCR system activation (pan-agonist needed)

MT-II

Higher activity across MC1R, MC3R, MC4R

MC4R-selective in vitro pharmacology

PT-141

Lower MC1R engagement; cleaner MC4R data

MC3R-focused studies with reduced MC1R background

Relative selectivity benefit

Pigmentation-related MC1R research

Higher MC1R potency

Comparative SAR studies on cyclic melanocortin scaffold

Both

Structural pair with single-variable difference

Reference standard for melanocortin receptor assays

Widely cited in published literature

Using MT-II and PT-141 Together in Research

Because MT-II and PT-II are structurally related but pharmacologically distinguishable, using both as paired tool compounds is a valid and common experimental strategy. By comparing effects at MC3R/MC4R systems activated by PT-141 versus the broader MCR activation produced by MT-II, researchers can draw inferences about the relative contribution of MC1R to observed biological outcomes in a given assay system.

For example, if a cellular response is observed with MT-II but not reproduced with PT-141 at equipotent MC4R concentrations, this suggests MC1R may be contributing to the MT-II response. This type of comparative pharmacology experiment represents one of the most rigorous applications of these two compounds in melanocortin receptor research.

Related Research Resources in This Cluster

Palmetto Peptides Guide to the Research Peptide PT-141 (Bremelanotide)

History of PT-141 Research Peptide: From Melanotan II Discoveries to Modern Laboratory Applications

PT-141 Chemical Structure, Sequence, and Molecular Properties for Research Use

PT-141 Mechanism of Action as a Melanocortin Receptor Agonist in Preclinical Research

Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays: A Research Applications Guide

PT-141 Structure-Activity Relationships: How Molecular Modifications Affect Melanocortin Receptor Research Outcomes

Frequently Asked Questions

Q: What is the main structural difference between PT-141 and Melanotan II? The C-terminus: MT-II has an amide (-NH₂), PT-141 has a free carboxyl (-OH). Both are cyclic heptapeptides sharing core structural features from the same research lineage.

Q: Is PT-141 more selective than Melanotan II? Yes, at MC1R. PT-141 shows lower MC1R activity, making it more suitable for experiments focused on MC3R or MC4R signaling.

Q: Which is better for MC4R research? PT-141 is generally preferred due to reduced MC1R background confound, allowing cleaner MC4R-specific experimental interpretation.

Q: Can they be used together? Yes. Pairing them allows researchers to infer the contribution of MC1R to observed biological effects by comparing responses at equimolar concentrations.

Q: Do they have similar storage stability? Yes. Both share the same core stability features and follow similar storage recommendations.

Citations

Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides. 2006;27(4):921-930.

Wikberg JE, Mutulis F. "Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction." Nature Reviews Drug Discovery. 2008;7(4):307-323.

Hruby VJ, et al. "Design and synthesis of cyclic melanocortin analogs." Journal of Medicinal Chemistry. 1995;38:3454-3461.

Chhajlani V, Wikberg JE. "Molecular cloning and expression of the human melanocyte stimulating hormone receptor cDNA." FEBS Letters. 1992;309(3):417-420.

Tao YX. "The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology." Endocrine Reviews. 2010;31(4):506-543.

Author: Palmetto Peptides Research Team

This article is for scientific and educational reference only. PT-141 and Melanotan II are research peptides sold exclusively for qualified laboratory use. Not intended for human or veterinary use. Researchers are responsible for all applicable regulatory compliance.

Part of the PT-141 Research Guide — Palmetto Peptides comprehensive research resource.

Related research: MT-2 complete research guide, and MT-2 melanocortin receptor mechanism.

See Also: Complete PT-141 Research Guide

Related PT-141 Research Articles

PT-141 vs MT-2: Comparing Melanocortin Research Peptides Side by Side

PT-141 Structure-Activity Relationships: Molecular Modifications and Melanocortin Receptor Research

Optimal Storage Conditions and Stability of PT-141 Research Peptide in Laboratory Settings

Best Practices for Handling and Preparing PT-141 Research Peptide in the Lab

Using PT-141 in Radioligand Binding and Cell-Based Receptor Assays

Order research-grade PT-141 (Bremelanotide) with batch-specific COA from Palmetto Peptides. See also Melanotan II and our full research peptide catalog.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Safely Source Peptides: Avoiding Scams and Poor Quality

Learn how to safely source research peptides by verifying Certificates of Analysis, recognizing red flags, understanding purity metrics, and ensuring proper storage. A complete guide to avoiding scams and low-quality suppliers.
DOSAGE SOURCE

Dosing & Reconstitution Guide

Two separate vials, dosed independently — reconstitute and measure each peptide on its own Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Peptide Legality: FDA Status, Research Use, and What's Legal

Peptides are legally classified based on FDA approval status, compounding rules, and intended use, not molecular structure. Learn what's legal, what's restricted, and what the gray areas mean for you.

RESEARCH

What the Evidence Actually Shows

Here it is essential to be precise about evidence levels, because this is where marketing most often outruns the science. The direct human evidence for Melanotan II and sexual function is small, old, and centered on male erectile response, not on female HSDD or on “desire” as a standalone outcome. The single most-cited human study is a 1998 double-blind, placebo-controlled crossover trial by Wessells and colleagues in which ten men with psychogenic (non-organic) erectile dysfunction received Melanotan II or placebo, with erections monitored objectively using RigiScan penile tumescence recording. Clinically apparent erections developed in 8 of 10 men after MT-II, and the mean duration of tip rigidity greater than 80% was 38.0 minutes with MT-II versus 3.0 minutes with placebo.1 A follow-up study by the same group extended the observation to men with organic erectile dysfunction and additionally noted increases in self-reported sexual desire alongside the erectile effect, which is the closest the MT-II literature gets to a “desire” endpoint.10 These were genuinely important proof-of-concept findings, but the sample sizes are in the single or low double digits, the populations were men with erectile dysfunction rather than people with HSDD, and the trials were not designed or powered to evaluate a desire disorder as a treatment indication. Wessells 19981 10 men, psychogenic ED Double-blind, placebo-controlled crossover, RigiScan Erection in 8/10; tip rigidity 38.0 vs 3.0 min Indirect (male erection, not desire) Wessells 200010 Men, organic ED Placebo-controlled Increased erection and self-reported desire Indirect (desire noted, small male sample) Dorr 1996 phase I3 Healthy men Pilot phase-I safety/pharmacology Incidental erections; tolerability signals Hypothesis-generating only Bremelanotide RECONNECT5 1,247 premenopausal women, HSDD Two randomized phase-3 RCTs Small significant gains in FSFI-D and distress Direct, but for bremelanotide, not MT-II Beyond those studies there is a large volume of preclinical and mechanistic work, plus the incidental phase-I observations that started the field.3,7 What is conspicuously absent is any randomized controlled trial of Melanotan II for HSDD in any population. There is no phase-2 or phase-3 program for MT-II in sexual desire, no regulatory submission, and no peer-reviewed efficacy dataset in women. The entire clinically robust HSDD evidence base belongs to the successor molecule, bremelanotide, and even there the effect size is modest, a point developed in the next section. It is also worth naming the study-design weaknesses that constrain how much even the positive MT-II findings can support. The Wessells crossover trials were small enough that a single outlier could move the mean, they enrolled men rather than the female population in which HSDD is most defined, and they used objective erectile monitoring as the primary readout, a physiological signal that is meaningfully different from the subjective, distress-linked desire that HSDD requires.1,10 Crossover designs are efficient but vulnerable to carryover and to unblinding when a drug produces obvious sensations such as flushing or nausea, which melanocortin agonists reliably do, and no MT-II study was ever scaled to the hundreds or thousands of participants needed to characterize efficacy and rarer harms. None of this makes the early findings worthless; they were a legitimate signal that launched an entire drug class. It simply means they sit near the bottom of the evidence hierarchy for a treatment claim, at the level of hypothesis-generating pilot data rather than confirmatory efficacy. So the honest summary of evidence level is: for Melanotan II specifically, the human data are limited to small early studies of male erectile response with incidental desire observations, supported by animal and receptor pharmacology. This qualifies as an interesting research signal and a legitimate open question, but it falls far short of the standard required to call MT-II a treatment for HSDD or anything else. Anyone claiming otherwise is either conflating MT-II with bremelanotide or overstating what a handful of ten-person crossover studies can establish. For a broader library of how individual compounds are characterized at the evidence level, DosagePeptide’s dosage protocol index is a useful orientation, but it is educational reference material, not clinical proof.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Selective versus Non-Selective: the Afamelanotide and Bremelanotide Comparison

The clearest way to understand Melanotan II’s place in pigmentation research is to see it against the two approved melanocortin drugs that flank it. The comparison is not academic…

Comparison

Central Versus Peripheral: The Blood-Brain Barrier Question

A recurring and honestly-contested question in the MT-II literature is whether the peptide’s appetite effect requires it to reach the brain, or whether peripheral administration —…

Comparison

Melanotan II Versus Related Melanocortin Compounds

Melanotan II is best understood in the context of its relatives, because vendors exploit the confusion among them and because the comparison clarifies what “approved” actually mea…

Continue reading

Related articles